BCMA CAR-T cell therapy / Xuzhou Medical University - LARVOL DELTA

Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Equecabtagene Autoleucel (Eque-cel, CT103A) in Fumanba-1 (ASH 2023) - P1/2 | "Pts who had progressed on previous BCMA CAR-T cell therapy were not included in this analysis. Based on our descriptive analysis, pts receiving eque-cel achieved MRD negativity irrespective of their high-risk cytogenetics, extramedullary disease, number of prior LOT and performance status. Presence of high tumor burden at baseline, and prior triple-class exposure might be factors that impact achievement of sustained MRD negativity. These data suggest that while eque-cel is effective for a broad range of pts, specific pt and disease characteristics may be associated with sustained MRD negativity and better long-term outcomes."

Clinical • IO biomarker • Minimal residual disease • Residual disease • Hematological Malignancies • Multiple Myeloma • Oncology

ASCTvsCAR-T: CAR-T vs. Auto-SCT: Which Works Better for New Myeloma Patients? (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: Xuzhou Medical University

New P2 trial • Bone Marrow Transplantation • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

A Study of Anti-BCMA CAR-T Therapy in Newly Diagnosed Myeloma Patients Who Are Transplant-ineligible (clinicaltrials.gov) - P=N/A | N=35 | Not yet recruiting | Sponsor: Xuzhou Medical University

New trial • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation